AGIX and AZN in License and Commercialization Agreement Worth Up to $1B
Tweet Send to a Friend
AtheroGenics, Inc. (Nasdaq: AGIX) entered into a licensing deal with AstraZeneca (NYSE: AZN) for the global development and commercialization of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
